# Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Doses of BIIL 284 BS in Healthy Male Volunteers

> **NCT02273414** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 35 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIIL 284 BS - rising dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02273414
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** 1999-09
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2014-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02273414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02273414, "Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Doses of BIIL 284 BS in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02273414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*